Montelukast Sun

Montelukast, the active ingredient in Montelukast Sun, is a leukotriene receptor antagonist presented as an oral dosage form for systemic use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in patients requiring long‑term control of airway inflammation. GNH USA supplies Montelukast Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to reduce airway inflammation and bronchoconstriction. - Asthma: decreases frequency of symptoms, improves lung function and reduces need for rescue inhalers. - Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes caused by seasonal allergens. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways that can occur during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Abdominal pain: discomfort or cramping in the stomach region. - Cough: transient irritation of the throat. - Nausea: feeling of queasiness, sometimes with mild vomiting. - Diarrhoea: loose stools occurring intermittently. - Fatigue: unusual tiredness or lack of energy.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat that may compromise breathing. - Stevens‑Johnson syndrome: severe skin reaction with blistering and detachment. - Hepatotoxicity: abnormal liver function tests indicating possible liver injury. - Mood changes: depression, anxiety or suicidal thoughts reported in rare cases. - Allergic rash: widespread hives or skin eruptions. - Anaphylaxis: rapid, life‑threatening allergic response requiring immediate medical care.

Before initiating therapy, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: weigh potential benefits against unknown risks to the infant. - Liver impairment: use with caution; dose adjustment may be required. - Age restrictions: not recommended for children under 12 years for certain indications without specialist advice. - Concomitant medications: review all current drugs for possible interactions. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with several medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Ritonavir: can increase montelukast plasma concentrations, raising the risk of adverse effects. - Phenobarbital: may markedly reduce montelukast exposure, diminishing therapeutic benefit.

Moderate Interactions (Monitor Closely): - Fluconazole: may elevate montelukast levels; monitor for side effects. - Warfarin: potential alteration of INR; regular coagulation monitoring advised. - Beta‑agonists: additive bronchodilator effect; assess for excessive bronchodilation.